Treating the Root Cause of Alzheimer’s
Dr. Elliot Goldstein, President & CEO of ProMIS Neurosciences speaks on the company’s developing treatments for Alzheimer’s and other neurodegenerative diseases.
“I’ve worked in pharmaceutical drug development in large pharmaceutical companies in biotech for just over 35 years, and drug development is my passion. ProMIS’ focus is to use our unique proprietary technology to identify and develop antibody therapies targeting neurodegenerative diseases, such as Alzheimer’s disease ALS and Parkinson’s disease. Neurodegenerative diseases, in particular the dementias like Alzheimer’s disease have no known therapy treating the root cause of the disease. At ProMIS we’re working to develop treatments that are selective for these diseases. Our platform allows us to identify targets on what is now known as the root cause of these diseases. In Alzheimer’s disease it’s widely appreciated now in the scientific community, the root cause are misfolded toxic oligomers of amyloid beta. We develop antibodies that specifically block these toxic forms. Our lead program PMN 310. We anticipate its initiation of clinical trials in 2019, so we are diligently moving forward and on track to achieve that. In addition, we continue to differentiate our lead program against other competitive therapies Alzheimer’s disease.” – Dr. Elliot Goldstein, President & CEO of ProMIS Neurosciences
ProMIS Neurosciences, Inc., is a development stage biotech company that discovers and develops precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).
For more information on ProMIS Neurosciences (PMN:TSX) please fill out the form below.